Entrada Therapeutics Total Revenue

As of the most recent data (June 2026), TRDA shows a total revenue of $4.7M. That compares with $79M in the prior-year period — down 94.1% year over year. That is below the sector sector average of $1.4B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TRDA's total revenue is now $4.7M (was $79M) — a 94.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Entrada Therapeutics is outperforming or lagging.

The its sector sector average total revenue is about $1.4B. Entrada Therapeutics is at $4.7M, which is lower that average. That is roughly 99.7% below the sector mean. Use the comparison chart on this page to see how TRDA stacks up against individual peers as well.

Tracking TRDA's total revenue over time shows whether Entrada Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $4.7M That compares with $79M in the prior-year period — down 94.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Entrada Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $4.7M) with ownership activity and broader fundamentals.